Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-08-07

FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

The FDA approved a supplemental application for DILANTIN Extended Phenytoin Sodium filed by Viatris Specialty LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DILANTIN (Phenytoin sodium, extended release)

Snippet

SUPPL AP for DILANTIN (EXTENDED PHENYTOIN SODIUM)